Alector Moves On To Alzheimer’s Drug After Latozinemab Flunks Phase III

 
• By Alaric DeArment
  
Alector announced the failure of its Phase III trial of latozinemab (Shutterstock)
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D